Kornimate/medical-research-clean huggingface dataset:
comparison of two treatments for strabismus correction: botulinum toxin a associated to surgery and surgery alone

Conditions: Esotropia; Exotropia

Summary: two different treatments were given to large angle horizontal strabismus (eso and exotropia) adult patients who agree to participate of the study. inform consents were required for participants. group 1 (12 patients) received conventional recess-resect surgery plus intraoperative injection of botulinum toxin a (5u). group 2 (11 patients) received only conventional recess-resect surgery. the patients were randomly located in one of the groups. the angles of horizontal deviation were compared between the groups before and six months after treatment.

patients underwent recess/resection surgery on the non-fixating eye using conventional technique under local anesthesia. the extent of surgery was determined based on our usual amounts. before re-attaching the recessed muscle to the sclera, 5 units of botulinum toxin in 0.1 ml of hyaline solution were, or 0.1 ml of hyaline solution alone were was injected into the posterior muscle belly by the surgeon who was unaware of the contents of each syringe.

Eligibility criteria:
inclusion criteria: * adults with large angle horizontal strabismus exclusion criteria: * oblique muscle disfunction * previous strabismus surgery * dissociated vertical deviation * paretic or restrictive deviation

Keywords: strabismus surgery botulinum toxin esotropia exotropia blepharoptosis
the global pchf-covicav registry

Conditions: COVID-19; Cardiovascular Diseases; Cardiovascular Risk Factor; Heart Failure

Summary: background: coronavirus disease (covid-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by covid-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease. aim: the purpose of the study is to characterise the clinical course of adult inpatients with covid-19 and concomitant cardiovascular affection in a worldwide, multicentre pchf registry. methods: retrospective and prospective data analysis. data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. the principal investigator provides dedicated electronic case report form. the primary outcome is in-hospital mortality. the secondary endpoints will be icu length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.


Eligibility criteria:
inclusion criteria: * adult inpatients (≥18 years old) with laboratory-confirmed covid-19. exclusion criteria: * age \<18 years old. * outpatients.

Keywords: covid-19 cardiovascular diseases cardiovascular risk factor heart failure
magnetic resonance imaging screening in li fraumeni syndrome

Conditions: Li-Fraumeni Syndrome

Summary: this study is aimed at exploring the use of whole body mri for early cancer detection in tp53 mutation carriers and population controls, with the hypothesis that more cancers will be detected in the tp53 mutation carrier group. a secondary end-point will be the number of incidental findings detected and subsequent investigations required. a series of questionnaires will be used to assess the psychological impact of screening on both the study and control group.


Eligibility criteria:
inclusion criteria: * carrier of germline tp53 mutation which, in the view of the geneticist, is not known to be low penetrance or non-related individual with no personal history of malignancy and no first degree relatives diagnosed with malignancy under the age of 50 years * please note, tp53 carrier cohort is complete and no longer open to recruitment * age between 18 and 60 * able to give informed consent exclusion criteria: * individual with low penetrance tp53 mutation * individual with tp53 variant of unknown significance. * previous malignancy diagnosed \< 5 years ago in tp53 carriers (except non-melanomatous skin cancer or cervical cis) previous history of malignancy in non-related controls (except non-melanomatous skin cancer or cervical cis) * current symptoms suggestive of malignancy * contraindication to mri (such as non-mr compatible metal implants) as specified by the standard mr safety checklist * claustrophobia * ecog performance status \>2

Keywords: li-fraumeni syndrome whole body magnetic resonance imaging tp53 psychological impact
title: comparison of anti-plaque efficacy of natural honey with chlorhexidine mouthwash: a randomized controlled trial

Conditions: Dental Plaque

Summary: the rationale of our study is to compare the efficacy of natural honey base preparation with other commercially available mouthwashes i.e chlorhexidine base in prevention of dental plaque formation as honey is readily available and cost effective and organic in nature. this study will help to provide the data of our community and positive result may provide a new method of oral hygiene maintenance with fewer side effects. we will be able to deliver the best anti-plaque agent.

in this study, participants will assigned into 2 group those who will fulfilled the inclusion and exclusion criteria. after the informed consent, they were divided into 2 group. group a will received chlorhexidine mouthwash and group b will provided with honey based mouthwash. the participant will blinded as solution will be provided in dark color bottle to mask the study. after which the baseline plaque index will be taken followed by recording plaque index on 7th, 14th, and 21st day. the statistical analysis will be done to compare the mean difference between these 2 groups

Eligibility criteria:
inclusion criteria: 1. individual aged between 18-25 2. retained 28 number of teeth excluding wisdom teeth exclusion criteria: 1. individual with medical illness affecting oral cavity like diabetes, sjögren syndrome, crohn disease etc 2. multiple extraction , overhang restoration, wearing any appliance 3. periodontal problem with pocket depth more than 3mm 4. current or recent history of antibiotic consumption 5. noncompliance that is unable to maintain their hygiene. 6. pan, betel quid and any other oral habit will not be included in study

Keywords: dental plaque, honey, chlorhexidine
fitness assessment in young adults recovered from lymphoma

Conditions: Young Adults; Lymphoma, Non-Hodgkin; Hodgkin Disease

Summary: regular physical activity (pa) is associated with maintaining body composition, increased cardiorespiratory capacity, muscle mass and bone mineral density. in the event of a cancer, the development of physical capacities and metabolism may therefore be disturbed by cancer, these associated treatments (chemotherapy, radiotherapy and hematopoietic stem cell transplantation) but also undernutrition and the reduction in physical activity or even a sedentary lifestyle. although the benefits of pa in oncology are now well identified for adult populations, studies are still rare in the population of children, adolescents and young adults, and the results are still difficult to generalize. as a result, there is no recommendation on the practice of physical activity in pediatric oncology or adolescents and young adults and the levels of physical activity of cured patients remain lower than those of the general population. fitness is a marker of health in adults as well as in adolescents. physical condition is a set of components such as cardiorespiratory capacity (transport and use of o2), body composition (distribution of bone, muscle and fat masses) and muscle function (strength, power, fatigue, energy metabolism) . the investigators hypothesize that, compared to young adults, recovered from lymphoma are expected to exhibit impaired physical condition, due to physical deconditioning.


Eligibility criteria:
inclusion criteria: * young adult male or female, aged 18 to 25 * giving free and informed consent * hodgkin lymphoma or non-hodgkin lymphoma in the healing stage * cured (defined by an undetectable disease at the end of treatment) for at least one year and maximum 6 years of lymphoma or hodgkin's disease exclusion criteria: * legal incapable adults * people under judicial protection * treatment with systemic glucocorticoids for more than a week, during the 30 days preceding the tests * medical contraindication to the practice of physical exercise * any pathologies (other than the history of lymphoma for the cases) likely to affect the metabolism or the muscle mass * any treatment that may have an influence on the energy metabolism * active infection * pregnant, breastfeeding, or likely to be * subject's refusal to participate

Keywords: physical fitness fat oxidation metabolism exercise
cytomegalovirus (cmv) infection in pregnancy

Conditions: Pregnancy Complications; Cytomegalovirus Infection

Summary: the purpose of this study is to determine if (recurrent) cytomegalovirus (cmv) infection of the mother results in pregnancy complications such as preterm delivery, severe preeclampsia, poor fetal growth, or stillbirth.

cmv infection in adults with a normal immune system is rarely a serious event. once a person has been infected with cmv, they may have recurrences (relapses) of the infection. if a mother is infected with the virus or relapses during pregnancy, her fetus may be at risk for infection. unlike infection in adults, fetal infection may result in serious complications (congenital infection). the effects of fetal infection with cmv are well understood and many efforts have been made to potentially reduce the risk of congenital infection. however, the effect of cmv infection on the pregnancy itself (when the fetus is not affected by cmv) is less understood. in this study, we plan to determine if cmv recurrence in the mother results in pregnancy complications. the pregnancy complications listed above have been associated with poor placental function. we also plan to determine if (recurrent) cmv infection in the mother is associated with cmv infection of the placenta.

Eligibility criteria:
inclusion criteria: * women who deliver at term without pregnancy complications * women who deliver (preterm, less than 37 weeks gestation) as a result of spontaneous preterm labor * women whose pregnancies are complicated by severe preeclampsia * women whose pregnancies are complicated by unexplained poor fetal growth (less than the 10th percentile). * women whose pregnancies are complicated by unexplained stillbirth. exclusion criteria: * women with multi-gestational pregnancies, or whose pregnancies are complicated by a congenital malformation or chromosomal abnormality. * women who have a medical history of hypertension (high blood pressure), diabetes, or severe renal (kidney) disease

Keywords: cytomegalovirus pregnancy placenta
phase ii fixed dose rate gemcitabine for advanced or metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: to assess the efficacy and safety of gemcitabine given by fixed dose rate intravenous infusion in patients with pretreated metastatic colorectal cancer.

previous lines of treatment recorded. adjuvant and palliative. treatment will continue until clinical indication due to pd or toxicity, or until completion of 6 cycles of gemcitabine, whichever comes first. all patients will be assessed for toxicity and followed up for disease recurrence/progression. the study will be divided into two accrual stages - the first consisting of 17 patients. if 6 or more patients achieve tumour response or stabilisation in the first stage, the second stage will commence accrual of a further 20 patients. hence, the total planned accrual will be 37 patients.

Eligibility criteria:
inclusion criteria: * age \>18 years * histologically proven colorectal adenocarcinoma. * locally advanced (inoperable) or metastatic colorectal carcinoma treated with at least one prior chemotherapy regimen. * progressive disease documented by ct either during or within 3 months of completion of previous chemotherapy * no previous malignant disease other than non-melanotic skin cancer or carcinoma-in-situ of the uterine cervix. * unidimensional measurable disease as assessed by ct. * adequate bone marrow function; hb \>10g/dl, platelets \>100 x109/l, wbc \>3x109/l, neut \>1.5x109/l. * adequate liver function: serum bilirubin \<1.5 x upper limit of normal * adequate renal function: serum creatinine \< 0.11 mmol/l * no concurrent uncontrolled medical conditions * who performance status 0,1 or 2 * adequate contraceptive precautions, if appropriate * informed written consent * negative pregnancy test in women of child bearing age * life expectancy \> 3 months exclusion criteria: * medical or psychiatric condition that comprise the patient's ability to take informed consent. * patients within 4 weeks of chemotherapy or radiotherapy (6 weeks for nitrosureas or mitomycin c). * previous treatment with gemcitabine. * patients with uncontrolled cerebral metastases.
surgery versus biologics for stricturing cd--a rct

Conditions: Crohn Disease

Summary: the management of stricturing crohn's disease (cd) remains challenging. although surgical resection may be the final way to solve it, the efficacy of biologics for symptomatic cd associated strictures was acceptable. in clinical practice, the chioce of treatment is particularly difficult. therefore, a clinical trial of biologics versus surgery is needed to assess which one is prefered.


Eligibility criteria:
inclusion criteria: 1. with intestinal obstructive symptoms; 2. confirmed intestinal strictures; 3. traditional drugs failed to induce remission; 4. envidence of active bowel inflammation; 5. inappropriate for ebd; 6. acquirement of written informed consent of participant; exclusion criteria: 1. unsuccessful medical treatment of intestinal obstruction; 2. complete obstruction; 3. contraindication for biologics; 4. penetrating disease; 5. short smaal bowel; 6. suspicion of bowel tumor; 7. no confirmed strictures; 8. comitant severe disese of other system; 9. obstructive symptoms under over 2 targets of biologics; 10. successful treatment with traditional drugs; 11. participate other clinical research.
study of ibreast, a handheld device to detect breast abnormalities during screening visits for breast cancer

Conditions: Breast Screening

Summary: this study will test the ibreastexam device to find out whether it can detect a mass or lump in the breast as accurately as a routine breast cancer screening examination. the ibreastexam is a handheld device that performs a painless electronic palpation (examination by touch) of the breast. the device is designed to detect breast abnormalities that may require breast imaging and additional clinical examination by a nurse or doctor. the ibreastexam device creates a color map of the breast, with red spots indicating areas that may be abnormal.


Eligibility criteria:
inclusion criteria: * female patient * over 18 years of age, able to consent * rlc patients presenting to rlc or baic for mammogram and cbe * asymptomatic and symptomatic patients will be included exclusion criteria: * male patients * patients under 18 years of age, unable to consent * pregnant patients * lactating patients * non-intact skin

Keywords: breast abnormalities
generalized anxiety disorder proof of concept efficacy and safety study of sep-225441 (eszopiclone) in gad subjects

Conditions: Generalized Anxiety Disorder

Summary: to determine the safety and efficacy of sep-225441 (eszopiclone) in subjects with generalized anxiety disorder (gad).

this is a multicenter, randomized, double blind, placebo controlled study of the safety and efficacy of sep-225441 (eszopiclone) in male and female adult subjects with a diagnosis of generalized anxiety disorder (gad). the study consists of a screening period of 7-10 days, 8 weeks of treatment, and a 7 day follow-up period. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
inclusion criteria: * male and female subjects must be between 18 and 50 years of age * subjects must have gad * subjects must be in otherwise good general health exclusion criteria: * subject has a documented history of hiv, hepatitis b or hepatitis c. * subject has a recent history (within 6 months of study entry) or current diagnosis of major depressive disorder, panic disorder (or 3 or more panic attacks in the past month). post traumatic stress disorder, body dysmorphic disorder, eating disorder, or other disorder. * subject has a history or presence of obsessive-compulsive disorder (ocd), any psychotic, bipolar or schizophrenic disorder. * subject has presence or history of antisocial personality or other severe disorder * subject has refractory gad (previously unresponsive to 2 or more adequate courses of ssri, snri, benzodiazepine or non-benzodiazepine treatment for gad). * subject has history of seizures, including febrile seizures. * subject has initiated psychotherapeutic intervention with 30 days; however, continued psychotherapy is allowed if stable and not specifically directed at gad. * subject is undergoing or has undergone electroconvulsive therapy. * subject is a current smoker or has smoked within the last 12 months. * subject has donated blood within the past 30 days or plans to donate during and within 30 days after study participation.

Keywords: anxiety
pharmacokinetics and safety/tolerability of ckd-379

Conditions: Type II Diabetes Mellitus

Summary: a study to compare the pharmacokinetics and safety/tolerability between ckd-379 tablet and d759, d745, d150 combination

a randomized, open-label, single dose, 2-period, 2-treatment, crossover study to compare the pharmacokinetics and safety/tolerability of ckd-379 in healthy subjects under fed conditions

Eligibility criteria:
inclusion criteria: * between 19 aged and 50 aged in healthy adult * 50.0kg≤body weight≤90.0kg and 18.0kg/m2≤body mass index(bmi)≤27.0kg/m2 exclusion criteria: * have clinical significant medical history or disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, digestive system, urinary system, endocrine system(type i or type ii diabetes mellitus, diabetic ketoacidosis etc.), hematological system, cardiovascular system(heart failure, torsades de pointes etc.), mental illness * have clinical significant medical history or disease that urinary tract infection or genital infection including urosepsis, pyelonephritis * have a gastrointestinal disease(crohn's disease, ulcer etc.) history that can effect drug absorption or surgery * those who are pregnant or breastfeeding * those who are deemed inappropriate to participate in clinical trial by investigators
outcomes of the modified-brostrom procedure using suture anchor for chronic lateral ankle instability

Conditions: Chronic Ankle Instability

Summary: this prospective, randomized study was conducted to compare the clinical outcomes of the modified brostrom procedure using a suture anchor and bone tunnel for chronic lateral ankle instability.

with with the increased number of participants in sports and leisure time activities, the incidence of ankle ligament injuries has been correspondingly increased. various surgical methods have been reported for chronic ankle instability. of these methods, the modified brostrom procedure is currently used most frequently, and its excellent treatment outcomes have been reported. if there are any methods for obtaining a strong ligament fixation force which are both technically simple and safe, such methods would shorten the operative time and be helpful for surgeons with little experience in managing chronic ankle instability to obtain excellent treatment outcomes. in recent years, a procedure using a suture anchor, which is used for various types of ligament or tendon reconstructions, has been frequently performed. to date, however, few studies have reported clinical outcomes of suture anchor techniques and comparisons of clinical results between suture anchor techniques and other procedures. given the above background, we prospectively compared the clinical outcomes between the bone tunnel and suture anchor techniques in the modified brostrom procedure for chronic lateral ankle instability.

Eligibility criteria:
inclusion criteria: * patients who complained of subjective instability of the ankle joint in whom repeated sprain injuries for \> 6 months and pain were confirmed * patients with marked ankle instability confirmed by the anterior drawer test as compared with the contralateral ankle joint and tenderness involving the lateral ligament of the ankle joint was confirmed on physical examination * patients with an talar tilt angle exceeding 10o or a discrepancy of \> 5o as compared with the non-affected side on stress radiography * patients with an anterior talar translation exceeding 10 mm or a discrepancy \> 3 mm as compared with the non-affected side. exclusion criteria: * patients who concurrently had an ankle fracture or marked tendon damage were excluded from the current analysis.

Keywords: ankle chronic lateral instability modified brostrom procedure suture anchor bone tunnel